Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06029465 · ClinicalTrials.gov registry record
Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials
A clinical trial, sponsored by Power Life Sciences.
- Not yet
- Registry status
- 500
- Enrollment target
NCT06029465 is a clinical trial that has not yet begun recruiting, run by Power Life Sciences. The registered enrollment target is 500 participants.
The verdict
NCT06029465 has not yet begun recruiting, sponsored by Power Life Sciences.
- NOT YET RECRUITING
- Registry status
- 500 participants
- Enrollment target
Study Summary
The study seeks to delve into the firsthand experiences of patients diagnosed with rhabdomyosarcoma who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. The data collected from this study will help improve future outcomes for all rhabdomyosarcoma patients as well as those in under-represented demographic groups.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-10 |
| Est. Completion | 2026-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06029465
The ClinicalTrials.gov registry entry for NCT06029465 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Power Life Sciences, which has 62 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06029465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06029465 about?
NCT06029465 is a clinical study titled "Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials". The study seeks to delve into the firsthand experiences of patients diagnosed with rhabdomyosarcoma who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these indiv...
What is the current status of trial NCT06029465?
This trial is currently not yet recruiting. The enrollment target is 500 participants. The study started on 2024-10. Estimated completion is 2026-10.
Who is sponsoring clinical trial NCT06029465?
This trial is sponsored by Power Life Sciences, which has 62 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.